跳至主要内容
临床试验/NCT02171182
NCT02171182已完成不适用

A Non-interventional Post-registration Clinical Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain

Astellas Pharma s.r.o.29 个研究点 分布在 1 个国家目标入组 319 人开始时间: 2014年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
319
试验地点
29
主要终点
Percentage rate of responders

研究概览

简要总结

The aim of this study is to monitor the effectiveness and used dosage of the 8% capsaicin patch in real-life clinical practice in the treatment of post-operative neuropathic pain.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosed peripheral post-operative neuropathic pain

排除标准

  • hypersensitivity to capsaicin
  • pregnancy
  • diabetes mellitus
  • treatment of face

研究组 & 干预措施

Qutenza patients w/ post-operative peripheral neuropathic pain

干预措施: Qutenza (Drug)

结局指标

主要结局

Percentage rate of responders

时间窗: Baseline, Week 13

at least 30% decrease in pain intensity as compared to the baseline

次要结局

  • Basic demographic parameters(Baseline)
  • Previous treatment of neuropathy(Baseline)
  • Reason for a change in the therapy(Baseline)
  • Dose(Baseline, Week 13 and Week 26)
  • Size of the area affected by neuropathic pain(Baseline, Week 13 and Week 26)
  • Concomitant neuropathic medication(Baseline, Week 13 and Week 26)
  • Efficacy of treatment(Baseline, Week 8, Week 13 and Week 26)
  • Quality of life questionnaire (EQ-5D)(Baseline, Week 8, Week 13 and Week 26)
  • Consumption of rescue analgesic medication(Baseline, Week 8, Week 13 and Week 26)
  • Consumption of additional medical care for neuropathic pain(Baseline, Week 8, Week 13 and Week 26)

研究者

发起方
Astellas Pharma s.r.o.
申办方类型
Industry
责任方
Sponsor

研究点 (29)

Loading locations...

相似试验